Next Article in Journal
Estimation of the Costs Attributable to Vitamin K Antagonist Treatment in Patients with Non-Valvular Atrial Fibrillation from a French Societal Perspective
Previous Article in Journal
Results and Validation of an Index to Measure Health State of Patients with Depression in Automated Healthcare Databases
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JMAHP
Volume 7
Issue 1
10.1080/20016689.2018.1562861
jmahp-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Perspectives to Mitigate Payer Uncertainty in Health Technology Assessment of Novel Oncology Drugs

by
Oriol Solà-Morales
1,*,
Timm Volmer
2 and
Lorenzo Mantovani
3
1
Health Innovation Technology Transfer and International, University of Catalonia, Barcelona, Spain
2
SmartStep Consulting GmbH, Hamburg, Germany
3
Centre for Public Health Research, University of Milan–Bicocca, Milan, Italy
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2019, 7(1), 1562861; https://doi.org/10.1080/20016689.2018.1562861
Submission received: 8 August 2018 / Revised: 9 December 2018 / Accepted: 20 December 2018 / Published: 22 January 2019

Abstract

Reimbursement decisions on new oncology drugs are now often made while uncertainty remains about a drug's risk–benefit profile. One consequence of this is a delay in patient access to valuable new medicines. We share our perspectives on strategies to mitigate sources of uncertainty in the health technology assessment process. These include flexible approaches for evaluating the additional benefit, such as better use of surrogate endpoints and health-related quality of life data, and renewed research efforts to define the optimal target population and generate real-world evidence post-authorisation.
Keywords: oncology; patient access; HTA; reimbursement; surrogate endpoint; Health Related Quality of Life (HRQoL) oncology; patient access; HTA; reimbursement; surrogate endpoint; Health Related Quality of Life (HRQoL)

Share and Cite

MDPI and ACS Style

Solà-Morales, O.; Volmer, T.; Mantovani, L. Perspectives to Mitigate Payer Uncertainty in Health Technology Assessment of Novel Oncology Drugs. J. Mark. Access Health Policy 2019, 7, 1562861. https://doi.org/10.1080/20016689.2018.1562861

AMA Style

Solà-Morales O, Volmer T, Mantovani L. Perspectives to Mitigate Payer Uncertainty in Health Technology Assessment of Novel Oncology Drugs. Journal of Market Access & Health Policy. 2019; 7(1):1562861. https://doi.org/10.1080/20016689.2018.1562861

Chicago/Turabian Style

Solà-Morales, Oriol, Timm Volmer, and Lorenzo Mantovani. 2019. "Perspectives to Mitigate Payer Uncertainty in Health Technology Assessment of Novel Oncology Drugs" Journal of Market Access & Health Policy 7, no. 1: 1562861. https://doi.org/10.1080/20016689.2018.1562861

APA Style

Solà-Morales, O., Volmer, T., & Mantovani, L. (2019). Perspectives to Mitigate Payer Uncertainty in Health Technology Assessment of Novel Oncology Drugs. Journal of Market Access & Health Policy, 7(1), 1562861. https://doi.org/10.1080/20016689.2018.1562861

Article Metrics

Back to TopTop